Altimmune Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +26.5% | -10.6% | -8.0% | -14.7% | -5.8% | +12.9% | +21.0% | +14.8% | +28.1% | +19.9% | +57.1% | |
| – | +37.0% | -10.5% | -8.7% | -14.9% | -5.8% | +13.1% | +21.4% | +15.0% | +28.4% | +20.3% | +0.0% | |
| – | +55.6% | -41.5% | -27.7% | -44.9% | +17.3% | +33.0% | +272.9% | -66.6% | -28.5% | +123.0% | -35.4% | |
| – | +40.5% | -8.0% | -9.4% | -15.5% | -5.4% | +13.6% | +22.2% | +15.1% | +29.7% | +21.2% | -1.6% | |
| – | +7.2% | -46.9% | +16.8% | +10.9% | -6.7% | -20.9% | -64.4% | -83.5% | +1,097.9% | -84.7% | +1,160.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.3% | -6.8% | +35.0% | -30.4% | +9.0% | -4.4% | +91.9% | +13.3% | +67.6% | -6.2% | +2.6% | |
| – | +2.3% | -6.7% | +33.7% | -43.0% | +21.2% | -6.4% | -5.9% | +36.7% | +19.0% | -24.5% | +10.4% | |
| – | +2.3% | +2.4% | -32.1% | -9.3% | -10.9% | -12.2% | -2.4% | +3.3% | +3.6% | +3.5% | – | |
| – | -32.0% | +81.6% | -28.5% | -57.8% | -81.4% | +410.4% | -21.0% | +464.5% | -43.4% | -43.7% | -16.9% | |
| – | – | – | – | – | – | – | – | +0.8% | +137.4% | +0.6% | +0.7% | |
| – | +29.1% | -10.9% | -11.8% | -12.6% | -7.4% | +15.1% | +13.5% | +15.0% | +21.2% | +26.3% | +67.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +9.0% | +21.1% | +0.2% | +0.2% | +0.2% | +6.0% | +7.8% | +9.7% | +12.5% | +23.7% | +49.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.